DC sculpture

Up on deck today we have some highlights from my notes from SITC18 session on Immune Escape: Current Understanding of Mechanisms and Advances in Therapeutics Approaches held on November 7th, 2018.

This is a topic that I find particularly fascinating, not least because it has distinct parallels with what we have learned from chemotherapy and targeted therapies over the last couple of decades, so why not immunotherapy too?

Semantically, I’m not hung up on terminology either – call it resistance or immune escape, the negative effect on therapy is what matters and even some of the mechanisms are similar, such as the development of JAK mutations, for example.

The important point there was plenty to think about and consider in terms of what the data tell us from the patient tumour analyses and where they might direct us in terms of future research as well as novel combination approaches.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by